US7147625B2 - Leg bag accessory - Google Patents

Leg bag accessory Download PDF

Info

Publication number
US7147625B2
US7147625B2 US10/611,301 US61130103A US7147625B2 US 7147625 B2 US7147625 B2 US 7147625B2 US 61130103 A US61130103 A US 61130103A US 7147625 B2 US7147625 B2 US 7147625B2
Authority
US
United States
Prior art keywords
sleeve
filter
accessory
accessory according
antimicrobial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/611,301
Other versions
US20050004525A1 (en
Inventor
Shantha Sarangapani
Fletcher Tifft Longley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICET Inc
Original Assignee
ICET Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICET Inc filed Critical ICET Inc
Priority to US10/611,301 priority Critical patent/US7147625B2/en
Publication of US20050004525A1 publication Critical patent/US20050004525A1/en
Application granted granted Critical
Publication of US7147625B2 publication Critical patent/US7147625B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
    • A61F5/44—Devices worn by the patient for reception of urine, faeces, catamenial or other discharge; Colostomy devices
    • A61F5/4404—Details or parts

Definitions

  • This invention relates to a leg bag accessory that connects a Foley catheter to a leg bag.
  • a leg bag accessory that contains an antimicrobial filter and a check valve.
  • Urinary drainage bag (“leg bags”) attached to indwelling urinary catheters (“Foley catheters”) are commonly used at hospitals and rehabilitation centers on long term and short term patients for incontinence after surgery, chronic disabilities, or other complications.
  • the leg bags are frequently one of the three major sources for an ascending infection that cause urinary tract infections (UTI) in patients. (The other two points of entry are the catheter-leg bag connection and the catheter-skin junction).
  • the leg bags become incubators for bacterial growth, most of which are pathogenic, such as e. coli, p. mirabilis, pseudomonas, Candida , and staph , and frequently antibiotic-resistant strains of those bacteria are present. While the leg bag is intended to keep contaminated urine from reentering the catheter, this nevertheless can occur and is one of the prime sources of UTI in patients.
  • CAUTI catheter-associated urinary tract infection
  • Extraluminal infection may occur early (with in 24–48 hrs of cathetrization) by direct inoculation when the catheter is inserted, or by organisms ascending from the perineum by capillary action in the thin mucous film contiguous to the external catheter surface.
  • the intraluminal infection occurs after an average of five to six days from organisms growing in the leg bag reaching the catheter.
  • leg bag Once colonized, the leg bag becomes a reservoir for bacteria to multiply unchecked and causes infection when contaminated urine refluxes up the catheter into the patient's bladder.
  • intraluminal contamination producing CAUTI occurs by a reflux of microorganisms gaining access to the catheter or from failure of closed drainage or by the slow migration of the microorganisms, mostly gram negative from the leg bag to the catheter and to the bladder eventually and accounts for about one-half of CAUTIs.
  • leg bag or bed bag collection systems are connected by a simple tube of varying length to the catheter.
  • the leg bag accessory of this invention is positioned between the collection system and the catheter, replacing the tube partially or fully.
  • the accessory prevents the reflux of contaminated urine from the leg bag through the catheter into the bladder.
  • the accessory employs a check valve to prevent the reflux of urine and an antimicrobial filter to impede the movement of microorganisms from the collection system to the catheter, inhibit their growth, and kill them.
  • the accessory provides a better quality of care to the patient.
  • the accessory is inexpensive, easy to use, and contains only biocompatible materials. It is an add-on to the collection system and the clinician can either use it or remove it if it is not needed.
  • FIG. 1 is a side view of a certain presently preferred embodiment of a leg bag accessory according to the present invention mounted between a Foley catheter and a leg bag.
  • FIG. 2 is a partially cut-away perspective view of the leg bag accessory shown in FIG. 1 .
  • FIG. 3 is a cross sectional view taken through III—III in FIG. 2 .
  • FIG. 4 is an inverted plan view of the reflux check valve shown in FIG. 1 .
  • FIG. 5 is a partially cut-away perspective view of a portion of another embodiment of a leg bag accessory according to this invention.
  • FIG. 6 is a cross-sectional view through VI—VI in FIG. 5 .
  • FIG. 7 is a graph showing the results of an in vitro study of a catheterized bladder mode with and without the using the accessory of this invention.
  • FIG. 8 is a graph showing the efficacy of the antimicrobial material from this invention after extensive washing in synthetic urine.
  • leg bag accessory 2 is connected by universal connector 3 to urinary catheter 4 .
  • catheter 4 has a tube 5 having a balloon 6 which is inflated by injecting sterile water into catheter 4 at inlet 7 after catheter 4 has been inserted into a bladder.
  • accessory 2 At the lower end 8 of accessory 2 is another universal connector 9 , which connects accessory 2 to collection leg bag 10 . Urine can be emptied from leg bag 10 through drain 11 .
  • accessory 2 comprises tubular sleeve 12 that encloses filter 13 having six passageways 14 therethrough.
  • Filter 13 is preferably an open-pore, sponge-like material, so that urine can pass through filter 13 as well as around it.
  • Sleeve 12 is preferably thermally welded, rather than glued, to connectors 9 and 11 so that the connections will be leak-free over the entire life of the accessory.
  • the inside surface of sleeve 12 is preferably covered with antimicrobial coating 15 .
  • check valve 16 has a flat portion 17 that sits on top of sleeve 12 and a duck-bill portion 18 .
  • Duck bill portion 18 has a narrow slit 19 at its base which permits urine to pass downward into accessory 2 , but inhibits the movement of urine upward into catheter 4 .
  • FIG. 4 shows a duck bill anti-reflux valve, other types of check valves can also be used, such as a ball in a chamber, or a flap over an aperture.
  • Sleeve 12 is preferably made of a flexible, transparent plastic such as silicone, polyethylene, polypropylene, polyurethane, or polycarbonate, but it could also be made of other materials, such as latex or polyvinylchoride; the preferred material is silicone because of its well-accepted biocompatibility.
  • Sleeve 12 is preferably cylindrical, but could also have other shapes, such a rectangular.
  • Sleeve 12 can be manufactured in various sizes to accommodate different patients. It may be, for example, about 2 to about 36 inches long and may have a diameter of about 0.2 to about 1 inch. Preferably, it has a length is about 2 to about 15 inches and a diameter of about 0.3 to about 0.7 inches.
  • a typical formula for antimicrobial coating 15 for a silicone sleeve can be made by diluting about 10 to about 30 wt % of an antimicrobial composition, such as the one used in Example 1, with a hexane solution of RTV (room temperature vulcanization) silicones (GE Plastics).
  • the mixture can be dip-coated or spray-coated onto the inner surface of the sleeve and dried at about 70° C. overnight.
  • medically approved polyurethanes such as Tecoflex (medical grade polyurethane) or Hypol ((a polyurethane prepolymer adhesive (Dow chemicals) or Polyvinyl chloride (PVC) can be dissolved in a solvent such as tetrahydrofuran or acetone.
  • An antimicrobial composition is blended into the polyurethanes or silicones and the mixture can be coated on the inside of the sleeve as described above. Such coated sleeve lengths range from 0.1′′ to 36′′ inches.
  • FIGS. 5 and 6 an alternative star-shaped filter 20 is shown.
  • Other filter configurations can also be used such as a multilumen configuration (a bundle of stacked tubes), a corrugated configuration (folded sheets), or a rolled configuration (a rolled up sheet).
  • the filter configuration is preferably selected so that urine flow is not occluded should sleeve 12 be severely flexed.
  • the configuration of filter 13 should be selected so that there is no passage past filter 13 that is outside the zone of inhibition.
  • the “zone of inhibition” is the distance from filter 13 in which bacteria are killed or inhibited from growing due to leaching of antimicrobial material from filter 13 . That is, filter 13 contains an antimicrobial material and is made to leach that antimicrobial material into urine passing through or around it. This antimicrobial material kills or inhibits the growth of any bacteria that are within the zone of inhibition, which is typically about 1 to about 3 mm from the surface of filter 13 .
  • the zone of inhibition is increased if more or more potent antimicrobial material is used, if more antimicrobial material leaches into the urine, or if the urine flow is slow; other factors may also affect the zone of inhibition.
  • Filter 13 is preferably biocompatable so that, in the very unlikely event that some of it finds its way up through the catheter into the bladder, it will not be harmful to the patient. Also, filter 13 preferably does not contain an antibiotic because that could promote the development of antibiotic-resistant bacteria.
  • the filter material is preferably made by compounding (i.e., heating at a temperature of about 160 to about 190° F.) a well-dispersed mixture of about 60 to about 90 wt % of a resin and about 10 to about 40 wt % of a antimicrobial composition.
  • the filter material is preferably about 70 to about 80 wt % resin and about 20 to about 30 wt % antimicrobial composition. More resin is undesirable because it would dilute the antimicrobial material and less resin is undesirable because the mechanical properties of the filter may be compromised.
  • suitable resins include sytrene-butadiene rubbers, polyurethanes, silicone-polyurethanes, polyvinylchloride, polyolefin elastomers, and silicone.
  • Materials such as inorganic/organic hybrid materials, carbon and other high area filled materials, such as nanocomposites, hydrogels such as polyoxazoline, polyvinylalcohol, polyhydroxy acrylates, super absorbent polymers, and biodegradable and natural polymeric materials such as cellulose or sponges, can also be used as carriers for the antimicrobial composition.
  • the preferred resins are polyurethane sold by Thermedics (MA) or a styrene-butadiene hybrid sold as Teknor, (Apex Teknor, RI) or Kraton sold by GLS Corp (IL) a distributor for Shell chemicals.
  • the resin particles can have a diameter of about 0.01 to about 3 mm (measured as if spherical); particle sizes less than about 0.01 mm are hard to obtain and particle sizes greater than about 3 mm are less desirable because they have less surface area; a particle size of about 2 to about 3 mm is preferred.
  • the antimicrobial composition preferably contains four components:
  • the purpose of the antimicrobial material is to kill bacteria, yeasts, and molds.
  • suitable antimicrobial materials include nanosize particles of metallic silver or silver containing about 2.5 wt % copper, salts such as silver citrate, silver acetate, silver benzoate, bismuth pyrithione, zinc pyrithione, sodium pyrithione, bismuth salts, various food preservatives such as methyl, ethyl, propyl, butyl, and octyl benzoic acid esters (generally referred to as parabens), citric acid.
  • Silver particles having a particle size of about 1 to about 100 nm are believed to slowly release silver ions, Ag+, which are antimicrobial.
  • Silver citrate is the preferred antimicrobial material because it is a very effective and safe bactericide due to the rapid release of silver ions.
  • Butyl paraben and octyl paraben are the preferred antimicrobial materials for yeasts and molds due to their low solubility in water.
  • About 60 to about 100 wt % of the antimicrobial composition can be the antimicrobial material; less is ineffective.
  • Preferably, about 35 to about 50 wt % of the antimicrobial material is used. The antimicrobial material slowly leaches from the filter, keeping the zone of inhibition free of live bacteria, yeasts, and molds.
  • the chelator prevents deposits of calcium and/or magnesium from forming, which may impede the flow of urine.
  • suitable chelators include EDTA, citric acid, hydroxyethylidene phosphonic acid, polyvinylphosphonic acid, polyvinylsulfonate, acrylic acid, and aminophosphonic acid.
  • the preferred chelator is citric acid because of its ability to solubilize silver and form complexes with calcium ions.
  • Zero to about 25 wt % (based on the weight of the antimicrobial composition) can be chelator. More is undesirable because of its acidity and less is undesirable because the efficacy of the long term release is reduced.
  • about 20 to about 30 wt % of the chelator is used.
  • the purpose of the pigment is for coloring, as the silver imparts a dark greyish color.
  • the addition of the pigment imparts a bluish grey shade.
  • Copper phthalocyanine (pigment blue) is the preferred pigment because it is believed to also have a bacteriostatic effect and is used in surgical sutures.
  • Zero to about 0.25 wt % (based on the weight of the antimicrobial composition) can be pigment. More is undesirable because of the high intensity in color and the blocking effect of the large pigment molecules and less is undesirable because the benefit of the color is lost (i.e., the color is visually not pleasing).
  • about 0.005 to about 0.01 wt % of the pigment is used.
  • the purpose of the lubricant is to make the surface lubricious, when contacted by aqueous fluids, such as urine which is advantageous because it helps to prevent bacteria from adhering to the filter.
  • suitable lubricants include polyethylene oxide, polyacrylic acid, polyvinylpyrrolidone, polyvinyl alcohol, and derivatives thereof.
  • the preferred lubricant is polyethylene oxide because it discourages cell adhesion and can be incorporated into the antimicrobial composition.
  • Zero to about 3 wt % (based on the weight of the antimicrobial composition) can be lubricant. More is undesirable because of processing issues and less is undesirable because the surface is less lubricious.
  • about 2 to about 3 wt % of the lubricant is used.
  • a preferred antimicrobial composition is about 10 to about 25 wt % silver citrate, about 5 to about 10 wt % nanosize (i.e., less than about ten nanometers) silver powder, about 5 to about 10 wt % EDTA or a vinyl phosphonic acid or hydroxy ethyl phosphonic acid, about 20 to about 40 wt % butyl paraben, about 10 to about 25 wt % citric acid about 10 to about 15 wt % hydroxyethylidene phosphonic acid, and about 2 to about 3 wt % polyethylene oxide.
  • suitable antimicrobial compositions are described in U.S. Pat. Nos. 5,328,954 and 5,877,243, the teachings of which are incorporated herein by reference.
  • the mixture of the resin and the antimicrobial composition can be extruded at about 100 to about 200° F. using the special die that forms the filter in the desired configuration.
  • the filter can also be formed by molding or shaping the mixture of the resin and the antimicrobial composition.
  • This example illustrates the ability of the accessory of this invention to protect a catheterized bladder from infection by blocking the ascending migration of bacteria from a contaminated leg bag.
  • An in vitro model was used.
  • the antimicrobial composition was blended as a fine powder and 68 gms of the powder was mixed with 386 gms of resin and pellets were formed by extruding at 180° F.
  • the pellets were then extruded through an 7 lumen die at 170 to 200° F. to form the filter material.
  • the filter material was packed into 4 inch long silicone tubes 0.5 inches in diameter which were connected to leg bags and catheters.
  • the control accessories contained the same length of silicone tube connector and a filter made with the same resin, but with no antimicrobial composition in it.
  • a simple physical model of the catheterized bladder and a drainage system was used with the leg bag accessory located between the base of the catheter and the leg bag inlet.
  • Synthetic urine containing tryptic soy broth (TSB) was supplied to the model at 0.5 mL/minute and the leg bag was contaminated with Escherichia coli and Proteus mirabilis strains isolated from UTI patients and leg bags, respectively. Over 10 to 15 days, urine from the leg bag accessory and the base of the catheter were examined for contamination.
  • the leachates from the antimicrobial leg bag accessory did not prevent the growth of the organisms in the leg bags.
  • visible discoloration and heavy encrustation were absent in the test leg bag systems compared to the control systems.
  • Scanning electron microscopy showed extensive biofilms on the control leg bag accessories.
  • a lawn growth was observed when samples from silicon sleeves from control leg bag accessories were cultured but the corresponding silicone sleeves from leg bag accessories according to this invention did not show any biofilms or any viable cells.
  • This example illustrates the performance of the antimicrobial filter material when subjected to continuous daily challenge of bacteria in human urine medium as well as in synthetic urine containing a rich broth called Brain Heart Infusion Broth (BHIB) or TSB (Tryptic soy broth) that facilitates the growth of bacteria.
  • BHIB Brain Heart Infusion Broth
  • TSB Traptic soy broth
  • one inch long samples of the antimicrobial filter material prepared in Example 1 were cut, weighed, and placed in two culture tubes with 0.5 mL of filter-sterilized human urine (HU) or synthetic urine or synthetic urine (SU) containing BHIB.
  • the urine was inoculated each with 1000 cfu/ml (colony forming units per ml) of three pathogens isolated from patients. (VA hospital- E. coli Hu734, a P. mirabilis strain, and Staphylococcus aureus ).
  • a tube containing only 0.5 ml of urine was prepared as a control and the organisms were inoculated. Each day samples were removed from the tubes, the media was replaced, and the samples were rechallenged. Aliquots were plated to quantify the bacterial growth.
  • Table II shows the efficacy of the antimicrobial filter material.
  • “SU” is synthetic urine
  • BHIB” is brain heart infusion broth.
  • This example illustrates the longevity of the antimicrobial action of the filter material when washed extensively with synthetic urine, simulating the daily urine flow output of about 1 L/day.
  • This example illustrates the antimicrobial release characteristics of the antimicrobial material from Example 1.
  • a sample of the filter material from Example 1 was consecutively extracted on a daily basis with filtered human urine or PBS under USP conditions (4 gms/20 ml) at 37° C. for 24 hrs.
  • the resulting solutions were analyzed for silver and paraben content. The results are given in the following table (Table III)
  • aqueous solution of 0.02 M NaCl was pumped into the inlets of the accessories to determine the resistance of the check valve to the flow of the solution pass it.
  • the test was conducted with a leg bag and a catheter properly attached and a pressure gage at the inlet. The reading of the pressure gage was at noise level and could be considered to be zero.
  • a U-tube filled with water was connected in between the pump and the catheter.
  • the saline solution was pumped pass the U-tube at a rate of 1 ml/min. There was no pressure increase from the flow of the saline solution into the accessory. When the pumping was stopped, the solution in the U-tube immediately drained into the accessory due to a siphon effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nursing (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • External Artificial Organs (AREA)
  • Materials For Medical Uses (AREA)

Abstract

An accessory is connected between a leg bag and a urinary catheter to prevent microorganisms migrating from the leg bag up through the catheter. The accessory has a sleeve, connectors to connect the sleeve to the leg bag and to the urinary catheter, a filter positioned within the sleeve that can be coated with an antimicrobial composition, and a valve to prevent fluid from moving from the leg bag to the catheter. The antimicrobial coated sleeve can be used with or with out the filter. The filter is made by compounding a polymeric resin powder with an antimicrobial composition.

Description

The invention reported here resulted from the work supported by the US National Institutes of Health Small Business Innovation Research (SBIR) Grant # 2R44 DK55891-022.
BACKGROUND OF THE INVENTION
This invention relates to a leg bag accessory that connects a Foley catheter to a leg bag. In particular, it relates to a leg bag accessory that contains an antimicrobial filter and a check valve.
Urinary drainage bag (“leg bags”) attached to indwelling urinary catheters (“Foley catheters”) are commonly used at hospitals and rehabilitation centers on long term and short term patients for incontinence after surgery, chronic disabilities, or other complications. The leg bags are frequently one of the three major sources for an ascending infection that cause urinary tract infections (UTI) in patients. (The other two points of entry are the catheter-leg bag connection and the catheter-skin junction). The leg bags become incubators for bacterial growth, most of which are pathogenic, such as e. coli, p. mirabilis, pseudomonas, Candida, and staph, and frequently antibiotic-resistant strains of those bacteria are present. While the leg bag is intended to keep contaminated urine from reentering the catheter, this nevertheless can occur and is one of the prime sources of UTI in patients.
Each year, more that 30 million urinary catheters are placed in patients in acute care hospitals and extended care facilities. Nosocomial (acquired at home or in nursing homes or hospitals) catheter-associated urinary tract infection (CAUTI) is the most common hospital-acquired infection in acute care hospitals, accounting for 40% of all nosocomial infections. (Stamm, W. E., “Catheter-associated urinary tract infections: Epidemiology, pathogenesis, and prevention,” Am J Med 91 (suppl 3B): 65S–71S, (1991); Burke, J. P. and Riley, D. K., Nosocomial urinary tract infection in hospital epidemiology and infection control. Mayhall, C. G., editor. Baltimore: Williams and Wilkins (1996), pp. 139–153; Maki, D. G., Tambyah, P. A. “Engineering out the risk of infection with urinary catheters,” Emer Inf Dis 7(2)1–5 (2001).) Nosocomial bacteriuria or candiduria develops in up to 25% of patients requiring a urinary catheter for at least 5 days, with a daily risk of 5%. (Stark, R. P. and Maki, D. G., “Bacteriuria in the catheterized patient,” N Engl J Med 311:560–4 (1984)) Catheter-associated urinary tract infection is the second most common cause of nosocomial bloodstream infections. (Maki, D. G., “Nosocomial bacteremia. An epidemiologic overview” Am J Med 70:719–32 (1981); Krieger, J. N. et al., “Urinary tract etiology of bloodstream infections in hospitalized patients,” J Infect Dis 148:57–62 (1983); Bryan, C. S. and Reynolds, K. L., “Hospital-acquired bacteremic urinary tract infection: epidemiology and outcome” J Urol 132:494–8 (1984)) Silent catheter-associated bacteriuria hosts an enormous reservoir of resistant organisms in the hospital which can be spread to other patients on the same units, particularly within ICUs (intensive care units). Studies by Platt and coworkers suggest that although most cases of catheter-associated bacteriuria are asymptomatic, CAUTI appears to be associated with significantly increased hospital mortality. (Platt, R. et al., “Mortality associated with nosocomial urinary tract infection.” N Engl J Med 307(11):637–641 (1982))
Most microorganisms causing endemic CAUTI derive from the patient's own colonic and perineal flora Extraluminal infection may occur early (with in 24–48 hrs of cathetrization) by direct inoculation when the catheter is inserted, or by organisms ascending from the perineum by capillary action in the thin mucous film contiguous to the external catheter surface. (Tambyah, P. A. et al., “A prospective study of pathogenesis of catheter-associated urinary tract infections,” Mayo Clin Proc 74(2): 131–6 (1999).) The intraluminal infection occurs after an average of five to six days from organisms growing in the leg bag reaching the catheter. Numerous strategies to prevent CAUTI have been examined in prospective trials, with the greatest success achieved by the use of sterile closed drainage systems. In a recent trial, use of a silver-hydrogel-coated catheter (Bardex® IC) to reduce the risk of extraluminally-acquired CAUTI was shown to reduce risk 25%, with no effect on the incidence of intraluminally-acquired CAUTIs, however. (Maki, D. G. et al., “A novel silver-hydrogel impregnated indwelling catheter reduces CAUTIs: a prospective double-blinded trial,” Abstract, Programs and Abstracts of the Society for Healthcare Epidemiology in America Annual Meeting; Apr. 5–7 (1998) Orlando, Fla.)
Other measures, such as the daily application of antiseptic solutions or antiseptic ointment to the catheterized meatus or perineum and the addition of antiseptic solutions to the collection bag, have given disappointing results. Bacteria commonly gain access to the collection system. (leg bag) Once colonized, the leg bag becomes a reservoir for bacteria to multiply unchecked and causes infection when contaminated urine refluxes up the catheter into the patient's bladder. Such intraluminal contamination producing CAUTI occurs by a reflux of microorganisms gaining access to the catheter or from failure of closed drainage or by the slow migration of the microorganisms, mostly gram negative from the leg bag to the catheter and to the bladder eventually and accounts for about one-half of CAUTIs.
SUMMARY OF THE INVENTION
Currently, the leg bag or bed bag collection systems are connected by a simple tube of varying length to the catheter. The leg bag accessory of this invention is positioned between the collection system and the catheter, replacing the tube partially or fully. The accessory prevents the reflux of contaminated urine from the leg bag through the catheter into the bladder. The accessory employs a check valve to prevent the reflux of urine and an antimicrobial filter to impede the movement of microorganisms from the collection system to the catheter, inhibit their growth, and kill them. The accessory provides a better quality of care to the patient.
Since an average amount of $39,000 per year per patient is currently spent in treating catheter-related infections and complications, the use of the accessory of this invention will significantly reduce hospital costs.
The accessory is inexpensive, easy to use, and contains only biocompatible materials. It is an add-on to the collection system and the clinician can either use it or remove it if it is not needed.
It is therefore a principal object of the present invention to provide a leg bag accessory that prevents or limits ascending infections between leg bags and the catheterized patient.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a side view of a certain presently preferred embodiment of a leg bag accessory according to the present invention mounted between a Foley catheter and a leg bag.
FIG. 2 is a partially cut-away perspective view of the leg bag accessory shown in FIG. 1.
FIG. 3 is a cross sectional view taken through III—III in FIG. 2.
FIG. 4 is an inverted plan view of the reflux check valve shown in FIG. 1.
FIG. 5 is a partially cut-away perspective view of a portion of another embodiment of a leg bag accessory according to this invention.
FIG. 6 is a cross-sectional view through VI—VI in FIG. 5.
FIG. 7 is a graph showing the results of an in vitro study of a catheterized bladder mode with and without the using the accessory of this invention.
FIG. 8 is a graph showing the efficacy of the antimicrobial material from this invention after extensive washing in synthetic urine.
 DESCRIPTION OF THE PREFERRED EMBODIMENTS
Referring to FIG. 1, the upper end 1 of leg bag accessory 2 is connected by universal connector 3 to urinary catheter 4. To prevent catheter 4 from becoming dislodged, catheter 4 has a tube 5 having a balloon 6 which is inflated by injecting sterile water into catheter 4 at inlet 7 after catheter 4 has been inserted into a bladder.
At the lower end 8 of accessory 2 is another universal connector 9, which connects accessory 2 to collection leg bag 10. Urine can be emptied from leg bag 10 through drain 11.
Referring now also to FIGS. 2 to 4, accessory 2 comprises tubular sleeve 12 that encloses filter 13 having six passageways 14 therethrough. Filter 13 is preferably an open-pore, sponge-like material, so that urine can pass through filter 13 as well as around it. Sleeve 12 is preferably thermally welded, rather than glued, to connectors 9 and 11 so that the connections will be leak-free over the entire life of the accessory. The inside surface of sleeve 12 is preferably covered with antimicrobial coating 15.
Referring particularly to FIG. 4, check valve 16 has a flat portion 17 that sits on top of sleeve 12 and a duck-bill portion 18. Duck bill portion 18 has a narrow slit 19 at its base which permits urine to pass downward into accessory 2, but inhibits the movement of urine upward into catheter 4. While FIG. 4 shows a duck bill anti-reflux valve, other types of check valves can also be used, such as a ball in a chamber, or a flap over an aperture.
Sleeve 12 is preferably made of a flexible, transparent plastic such as silicone, polyethylene, polypropylene, polyurethane, or polycarbonate, but it could also be made of other materials, such as latex or polyvinylchoride; the preferred material is silicone because of its well-accepted biocompatibility. Sleeve 12 is preferably cylindrical, but could also have other shapes, such a rectangular. Sleeve 12 can be manufactured in various sizes to accommodate different patients. It may be, for example, about 2 to about 36 inches long and may have a diameter of about 0.2 to about 1 inch. Preferably, it has a length is about 2 to about 15 inches and a diameter of about 0.3 to about 0.7 inches.
A typical formula for antimicrobial coating 15 for a silicone sleeve can be made by diluting about 10 to about 30 wt % of an antimicrobial composition, such as the one used in Example 1, with a hexane solution of RTV (room temperature vulcanization) silicones (GE Plastics). The mixture can be dip-coated or spray-coated onto the inner surface of the sleeve and dried at about 70° C. overnight. For other plastics, medically approved polyurethanes such as Tecoflex (medical grade polyurethane) or Hypol ((a polyurethane prepolymer adhesive (Dow chemicals) or Polyvinyl chloride (PVC) can be dissolved in a solvent such as tetrahydrofuran or acetone. An antimicrobial composition is blended into the polyurethanes or silicones and the mixture can be coated on the inside of the sleeve as described above. Such coated sleeve lengths range from 0.1″ to 36″ inches.
Referring now to FIGS. 5 and 6, an alternative star-shaped filter 20 is shown. Other filter configurations can also be used such as a multilumen configuration (a bundle of stacked tubes), a corrugated configuration (folded sheets), or a rolled configuration (a rolled up sheet). The filter configuration is preferably selected so that urine flow is not occluded should sleeve 12 be severely flexed. In addition, the configuration of filter 13 should be selected so that there is no passage past filter 13 that is outside the zone of inhibition.
The “zone of inhibition” is the distance from filter 13 in which bacteria are killed or inhibited from growing due to leaching of antimicrobial material from filter 13. That is, filter 13 contains an antimicrobial material and is made to leach that antimicrobial material into urine passing through or around it. This antimicrobial material kills or inhibits the growth of any bacteria that are within the zone of inhibition, which is typically about 1 to about 3 mm from the surface of filter 13. The zone of inhibition is increased if more or more potent antimicrobial material is used, if more antimicrobial material leaches into the urine, or if the urine flow is slow; other factors may also affect the zone of inhibition.
Filter 13 is preferably biocompatable so that, in the very unlikely event that some of it finds its way up through the catheter into the bladder, it will not be harmful to the patient. Also, filter 13 preferably does not contain an antibiotic because that could promote the development of antibiotic-resistant bacteria.
The filter material is preferably made by compounding (i.e., heating at a temperature of about 160 to about 190° F.) a well-dispersed mixture of about 60 to about 90 wt % of a resin and about 10 to about 40 wt % of a antimicrobial composition. The filter material is preferably about 70 to about 80 wt % resin and about 20 to about 30 wt % antimicrobial composition. More resin is undesirable because it would dilute the antimicrobial material and less resin is undesirable because the mechanical properties of the filter may be compromised. Examples of suitable resins include sytrene-butadiene rubbers, polyurethanes, silicone-polyurethanes, polyvinylchloride, polyolefin elastomers, and silicone. Materials such as inorganic/organic hybrid materials, carbon and other high area filled materials, such as nanocomposites, hydrogels such as polyoxazoline, polyvinylalcohol, polyhydroxy acrylates, super absorbent polymers, and biodegradable and natural polymeric materials such as cellulose or sponges, can also be used as carriers for the antimicrobial composition. The preferred resins are polyurethane sold by Thermedics (MA) or a styrene-butadiene hybrid sold as Teknor, (Apex Teknor, RI) or Kraton sold by GLS Corp (IL) a distributor for Shell chemicals. The resin particles can have a diameter of about 0.01 to about 3 mm (measured as if spherical); particle sizes less than about 0.01 mm are hard to obtain and particle sizes greater than about 3 mm are less desirable because they have less surface area; a particle size of about 2 to about 3 mm is preferred.
The antimicrobial composition preferably contains four components:
(1) antimicrobial material;
(2) calcium chelator;
(3) pigment; and
(4) lubricant.
The purpose of the antimicrobial material is to kill bacteria, yeasts, and molds. Examples of suitable antimicrobial materials include nanosize particles of metallic silver or silver containing about 2.5 wt % copper, salts such as silver citrate, silver acetate, silver benzoate, bismuth pyrithione, zinc pyrithione, sodium pyrithione, bismuth salts, various food preservatives such as methyl, ethyl, propyl, butyl, and octyl benzoic acid esters (generally referred to as parabens), citric acid. Silver particles having a particle size of about 1 to about 100 nm are believed to slowly release silver ions, Ag+, which are antimicrobial. Silver citrate is the preferred antimicrobial material because it is a very effective and safe bactericide due to the rapid release of silver ions. Butyl paraben and octyl paraben are the preferred antimicrobial materials for yeasts and molds due to their low solubility in water. About 60 to about 100 wt % of the antimicrobial composition can be the antimicrobial material; less is ineffective. Preferably, about 35 to about 50 wt % of the antimicrobial material is used. The antimicrobial material slowly leaches from the filter, keeping the zone of inhibition free of live bacteria, yeasts, and molds.
The chelator prevents deposits of calcium and/or magnesium from forming, which may impede the flow of urine. Examples of suitable chelators include EDTA, citric acid, hydroxyethylidene phosphonic acid, polyvinylphosphonic acid, polyvinylsulfonate, acrylic acid, and aminophosphonic acid. The preferred chelator is citric acid because of its ability to solubilize silver and form complexes with calcium ions. Zero to about 25 wt % (based on the weight of the antimicrobial composition) can be chelator. More is undesirable because of its acidity and less is undesirable because the efficacy of the long term release is reduced. Preferably, about 20 to about 30 wt % of the chelator is used.
The purpose of the pigment is for coloring, as the silver imparts a dark greyish color. The addition of the pigment imparts a bluish grey shade. Copper phthalocyanine (pigment blue) is the preferred pigment because it is believed to also have a bacteriostatic effect and is used in surgical sutures. Zero to about 0.25 wt % (based on the weight of the antimicrobial composition) can be pigment. More is undesirable because of the high intensity in color and the blocking effect of the large pigment molecules and less is undesirable because the benefit of the color is lost (i.e., the color is visually not pleasing). Preferably, about 0.005 to about 0.01 wt % of the pigment is used.
The purpose of the lubricant is to make the surface lubricious, when contacted by aqueous fluids, such as urine which is advantageous because it helps to prevent bacteria from adhering to the filter. Examples of suitable lubricants include polyethylene oxide, polyacrylic acid, polyvinylpyrrolidone, polyvinyl alcohol, and derivatives thereof. The preferred lubricant is polyethylene oxide because it discourages cell adhesion and can be incorporated into the antimicrobial composition. Zero to about 3 wt % (based on the weight of the antimicrobial composition) can be lubricant. More is undesirable because of processing issues and less is undesirable because the surface is less lubricious. Preferably, about 2 to about 3 wt % of the lubricant is used.
A preferred antimicrobial composition is about 10 to about 25 wt % silver citrate, about 5 to about 10 wt % nanosize (i.e., less than about ten nanometers) silver powder, about 5 to about 10 wt % EDTA or a vinyl phosphonic acid or hydroxy ethyl phosphonic acid, about 20 to about 40 wt % butyl paraben, about 10 to about 25 wt % citric acid about 10 to about 15 wt % hydroxyethylidene phosphonic acid, and about 2 to about 3 wt % polyethylene oxide. Other examples of suitable antimicrobial compositions are described in U.S. Pat. Nos. 5,328,954 and 5,877,243, the teachings of which are incorporated herein by reference.
To make the filter, the mixture of the resin and the antimicrobial composition can be extruded at about 100 to about 200° F. using the special die that forms the filter in the desired configuration. The filter can also be formed by molding or shaping the mixture of the resin and the antimicrobial composition.
EXAMPLE 1
This example illustrates the ability of the accessory of this invention to protect a catheterized bladder from infection by blocking the ascending migration of bacteria from a contaminated leg bag. An in vitro model was used.
A antimicrobial composition was prepared of 7 wt % nanosize silver particles (from Nanopowder Industries, Israel), 18 wt % silver citrate (Aldrich), 36 wt % butyl parabens (Sigma Aldrich), 34 wt % citric acid (Sigma Aldrich), 0.25 wt % copper phthalocyanine (Aldrich, Minn.), 1.75 wt % polyethylene oxide (MW=100,000), and 3 wt % EDTA. The antimicrobial composition was blended as a fine powder and 68 gms of the powder was mixed with 386 gms of resin and pellets were formed by extruding at 180° F. The pellets were then extruded through an 7 lumen die at 170 to 200° F. to form the filter material. The filter material was packed into 4 inch long silicone tubes 0.5 inches in diameter which were connected to leg bags and catheters. The control accessories contained the same length of silicone tube connector and a filter made with the same resin, but with no antimicrobial composition in it.
A simple physical model of the catheterized bladder and a drainage system was used with the leg bag accessory located between the base of the catheter and the leg bag inlet. Synthetic urine containing tryptic soy broth (TSB) was supplied to the model at 0.5 mL/minute and the leg bag was contaminated with Escherichia coli and Proteus mirabilis strains isolated from UTI patients and leg bags, respectively. Over 10 to 15 days, urine from the leg bag accessory and the base of the catheter were examined for contamination.
Bacteriological analysis showed that the mean time for the bacteria to reach the catheter base for three separate studies ranged from 3 days to 8 days for the control leg bag accessories. Urine from the catheter bases of the leg bag accessories with the accessories remained sterile for over 14 days, when the reactor was stopped, as shown in Table I and FIG. 7. These “in vitro” tests suggest a useful role for the accessory in controlling infection in patients undergoing short and long term in-dwelling catheterization.
TABLE I
Antimicrobial
Material Control CHI
Total No. of % with Total No. of % with SQUARE P
RUN SAMPLING SITES Samples Growth Samples Growth VALUES
5 Catheter Base 15 0.0% 15 73.3% p < 0.0001
6 Leg Bag Only 18 53.8% 18  100% p = 0.005
7 Catheter base 16 0.0% 15 73.3% p = 0.0003
8 Tube Bottom* 10 0.0% 12 58.3% p = 0.020
*Part of the same connecting tube that is proximal to the leg bag inlet.
The leachates from the antimicrobial leg bag accessory did not prevent the growth of the organisms in the leg bags. However, visible discoloration and heavy encrustation were absent in the test leg bag systems compared to the control systems. Scanning electron microscopy showed extensive biofilms on the control leg bag accessories. Typically, a lawn growth was observed when samples from silicon sleeves from control leg bag accessories were cultured but the corresponding silicone sleeves from leg bag accessories according to this invention did not show any biofilms or any viable cells.
EXAMPLE 2
This example illustrates the performance of the antimicrobial filter material when subjected to continuous daily challenge of bacteria in human urine medium as well as in synthetic urine containing a rich broth called Brain Heart Infusion Broth (BHIB) or TSB (Tryptic soy broth) that facilitates the growth of bacteria.
In this example, one inch long samples of the antimicrobial filter material prepared in Example 1 were cut, weighed, and placed in two culture tubes with 0.5 mL of filter-sterilized human urine (HU) or synthetic urine or synthetic urine (SU) containing BHIB. The urine was inoculated each with 1000 cfu/ml (colony forming units per ml) of three pathogens isolated from patients. (VA hospital-E. coli Hu734, a P. mirabilis strain, and Staphylococcus aureus). A tube containing only 0.5 ml of urine was prepared as a control and the organisms were inoculated. Each day samples were removed from the tubes, the media was replaced, and the samples were rechallenged. Aliquots were plated to quantify the bacterial growth. Table II shows the efficacy of the antimicrobial filter material. In the table, “SU” is synthetic urine and “BHIB” is brain heart infusion broth.
TABLE II
Results of the continuous challenge tests.
With antimicrobial Control
Microorganism Composition Total No. CHI
Approx: 1000 cells Total No. of % with of % with SQUARE
Run each Media Challenges Growth Challenges Growth P Values
1 E. coli + 90 wt % SU + 39 23.1% 13 84.6% <0.0001
P. mirabilis 10 wt % BHIB
2 E. coli + 90 wt % SU 46 4.3% 21 90.4% <0.0001
P. mirabilis and 10 wt %
TSB
3 E. coli 90 wt % 19 5.3% 18  100% <0.0001
SU + 10 wt %
TSB
4 E. coli + HU 32 3.2% 16 81.3% <0.0001
P. mirabilis
5 S. aureus HU 24 0.0% 12 83.3% <0.0001
The results were analyzed by comparing the percent of samples that were found to be non-sterile for the antimicrobial filter material vs. the control filter material. In this situation, the most straightforward comparison is simply 2×2 contingency tables using the number of samples in each category: antimicrobial filter material vs. control filter material for sterile vs. non-sterile samples using all the samples as random tests. The data was then analyzed by Chi-square testing (or Fisher Exact for small numbers) with the null hypothesis that there is no difference between the adjusted categories. As can be seen in Table II, the differences are highly significant.
EXAMPLE 3
This example illustrates the longevity of the antimicrobial action of the filter material when washed extensively with synthetic urine, simulating the daily urine flow output of about 1 L/day.
In long term wash and challenge studies, about 30 2-inch long pieces of the antimicrobial material of Example 1 and 30 2-inch long pieces of the control silicone were suspended and washed by gentle stirring in 1 L of filter sterilized simulated urine solution containing 1% TSB in a 1 L bottle. Both the controls and the antimicrobial material were suspended in the same bottle with change of solution every 24 hours. Duplicate samples at various time points were subjected to challenge by inoculation of clinical strains followed by incubation in real human urine. The clinical strains resistant to certain antibiotics tested were S. aureus, (SA), S. epidermidis, (SE), Coagulase negative Staph aureus (CN), Pseudomonas aeruginosa, Klebsiella pneumoniae, (KP), Vancomycin resistant enterococcus (EF), E. coli (EC), Candida (Can), and Proteus mirabilis (PM). These strains were isolated from venous and urinary catheters and blood culture bottles supplied by the VA Hospital in W. Roxbury, Mass. When tested by challenging them with high number of microorganisms, the results shown in FIG. 8 were obtained. Note the significant absence of microbial growth in the presence of the antimicrobial material. Where growth was noted in some samples, it was less than 100 colonies compared to confluent lawns in the controls. The results, shown in FIG. 8, illustrate the consistent efficacy of the antimicrobial material in inhibiting bacterial growth for up to 21 days.
EXAMPLE 4
This example illustrates the antimicrobial release characteristics of the antimicrobial material from Example 1. A sample of the filter material from Example 1 was consecutively extracted on a daily basis with filtered human urine or PBS under USP conditions (4 gms/20 ml) at 37° C. for 24 hrs. The resulting solutions were analyzed for silver and paraben content. The results are given in the following table (Table III)
TABLE III
Daily concentrations of silver and paraben released from
the antimicrobial material.
Extraction Butyl Paraben Silver
medium HU PBS HU PBS
Day 1 190 ppm 159 11 ppm 0.78
Day 2 341 166 11 1.0
Day 3 220 185 9 0.41
Day 4 404 177 7 0.4
Day 5 200 173 6 0.4
Day 6 166 0.41
Day 7 180 0.39

The above table shows there is a near steady release of the components from the antimicrobial filter. The HU extracted ten times more than PBS. Since 1 ppm of silver is biocidal, the concentrations near the surface of the antimicrobial device were high enough to prevent the migration of microorganisms past the filter.
EXAMPLE 5
Three leg bag accessories 8 inches long by 0.5 inches in diameter, fitted with “duck bill” anti-reflux check valves, as shown in FIGS. 2 and 4, were tested. Water was slowly pumped into the outlet of each accessory up to the check valve. Pressure was controlled by splitting the pump outlet, with one part going to check valve and the other part going to a needle valve and recycling to the pump reservoir. The pressure was increased in increments of 2 psi from a pressure of 2 psi to a pressure of 20 psi, holding at each pressure for 5 minutes. None of the valves failed in the three accessories tested. The procedure was repeated in increments from 11 to 14 psi up to 27 to 30 psi. One valve inverted at 27 to 30 psi, which is a much greater pressure than the valve would normally be subjected to.
An aqueous solution of 0.02 M NaCl was pumped into the inlets of the accessories to determine the resistance of the check valve to the flow of the solution pass it. The test was conducted with a leg bag and a catheter properly attached and a pressure gage at the inlet. The reading of the pressure gage was at noise level and could be considered to be zero.
To give a more precise reading at low pressures, a U-tube filled with water was connected in between the pump and the catheter. The saline solution was pumped pass the U-tube at a rate of 1 ml/min. There was no pressure increase from the flow of the saline solution into the accessory. When the pumping was stopped, the solution in the U-tube immediately drained into the accessory due to a siphon effect.
While the foregoing invention has been described with respect to its preferred embodiments, various alterations and modifications may occur to those skilled in the art. All such alterations and modifications are intended to fall within the scope of the appended claims.

Claims (19)

1. An accessory for connecting in between a urinary catheter and a leg bag comprising
(A) a sleeve having an upper end and a lower end;
(B) connectors for connecting the upper end of said sleeve to said urinary catheter and the lower end of said sleeve to said leg bag;
(C) a filter within said sleeve that comprises about 70 to about 90 wt % compounded polymeric resin and about 10 to about 30 wt % antimicrobial composition; and
(D) a valve within said sleeve at said upper end for impeding the flow of fluid from said accessory into said urinary catheter.
2. An accessory according to claim 1 wherein said sleeve is a natural rubber or a synthetic polymer.
3. An accessory according to claim 2 wherein said sleeve is a continuous part of the leg bag or the catheter.
4. An accessory according to claim 1 wherein said sleeve is about 0.1 to about 36 inches long and about 0.2 to about 1 inch in diameter.
5. An accessory according to claim 1 wherein the inside surface of said sleeve is coated with an antimicrobial coating.
6. An accessory according to claim 1 wherein said connectors are thermally welded or adhesively bonded to said sleeve.
7. An accessory according to claim 1 wherein said filter is extruded.
8. An accessory according to claim 1 wherein said filter is a bundle of separate tubes.
9. An accessory according to claim 1 wherein said filter has a star-shaped configuration.
10. An accessory according to claim 1 wherein said filter has a multiluminal configuration.
11. An accessory according to claim 1 wherein said filter has a folded configuration.
12. An accessory according to claim 1 wherein said valve occupies a space above said filter.
13. An accessory according to claim 1 wherein said polymeric resin is selected from the group consisting of polyurethanes, polyurethane sponges, styrene-butadiene based polymers, their blends or copolymers or derivatives, and silicone, or blends or and its copolymers.
14. An accessory according to claim 1 wherein said polymeric resin has a particle size of about 0.01 to about 3 mm in diameter.
15. An accessory according to claim 1 wherein said polymeric resin is selected from a group comprising common plastics, polymer resins, including inorganic/organic hybrid materials, carbon and other high area filled materials such as nanocomposites, superabsorbent polymers, hydrogels, biodegradable and natural polymeric materials such as cellulose or sponges and synthetic sponges.
16. An accessory according to claim 1 wherein said antimicrobial composition comprises
(A) about 60 to about 100 wt % of an antimicrobial material;
(B) 0 to about 25 wt % of a calcium chelator;
(C) 0 to about 0.25 wt % of a pigment; and
(D) 0 to about 3 wt % of a lubricant.
17. An accessory according to claim 1 wherein said antimicrobial composition comprises
(A) about 30 to about 60 wt % of a bactericide selected from the group consisting nanosize particles of silver, nanosize particles of silver with 2.5 wt % copper, silver citrate, silver acetate, silver benzoate, bismuth salicylate, bismuth pyrithione, zinc pyrithione, bismuth salts, parabenzoic acid ester, citric acid, sodium pyrithione, and mixtures thereof;
(B) about 20 to about 30 wt % of a calcium, chelator selected from the group consisting of ethylene diamine tetra acetic acid, citric acid, hydroxyethylidene phosphonic acid, polyvinylphosphonic acid, polyvinylsulfonate, poly acrylic acid, aminophosphonic acids, and mixtures thereof;
(D) about 0.005 to about 0.01 wt % copper phthalocyanine; and
(E) about 2 to about 3 wt % of a lubricant selected from the group consisting of polyethylene oxide, polyvinylpyrrolidone, polyacrylic acid polyvinyl alcohol, and derivatives and mixtures thereof.
18. An accessory for connecting a leg bag to a urinary catheter comprising
(A) a flexible plastic sleeve having an upper end and a lower end;
(B) plastic connectors for connecting the upper end of said sleeve to said urinary catheter and the lower end of said sleeve to said leg bag;
(C) a filter within said sleeve having a zone of inhibition that includes all passages therethrough and therearound, where said filter comprises a compounded mixture of
(1) about 60 to about 90 wt % polymeric resin powder; and
(2) about 10 to about 40 wt % of a antimicrobial composition that comprises
(a) about 35–67% of an antimicrobial for bacteria and fungi;
(b) about 14 to about 29 wt % of a calcium chelator;
(C) about 0.05 to about 0.1 wt % of a pigment; and
(d) about 2 to about 3 wt % of a lubricant; and
(D) a valve within said sleeve at said upper end for impeding the flow of fluid out of said accessory and into said urinary catheter.
19. An accessory for connecting in between a leg bag and a urinary catheter comprising
(A) a plastic sleeve having an upper end and a lower end;
(B) a first plastic connector thermally welded to the upper end of said sleeve for connecting said sleeve to said urinary catheter and a second plastic connector thermally welded to the lower end of said sleeve for connecting said sleeve to said leg bag;
(C) a filter occupying the space within said sleeve except near said upper end of said sleeve and having a zone of inhibition that includes all passages therethrough and therearound, where said filter comprises an extruded, molded, or shaped material that comprises
(1) about 70 to about 90 wt % polymeric resin powder selected from the group consisting of styrene-butadiene hybrids, polyurethanes, copolymers and hybrids thereof, silicones and hybrids, cellulose powder, hydrogels such as polyacrylates, polyoxazoline, alginates, p-hema, (polyhydroxy ethyl acrylate) polyvinylalcohol and its copolymers, and mixtures thereof; and
(2) about 10 to about 30 wt % a antimicrobial composition that comprises
(a) about 10 to about 25 wt % silver citrate;
(b) about 5 to about 8 wt % nanosilver containing about 2.5 wt % copper;
(c) about 20 to about 35 wt % butyl paraben;
(d) about 10 to about 25 wt % citric acid;
(e) about 0.1 to about 0.25 wt % copper phthalocyanine; and
(f) about 4 to about 5 wt % ethylene diamine tetraacetic acid; and
(g) about 2 to about 3 wt % polyethylene oxide; and
(D) a duck bill check valve within said sleeve at said upper end for impeding the flow of fluid out of said accessory and into said urinary catheter.
US10/611,301 2003-07-01 2003-07-01 Leg bag accessory Expired - Fee Related US7147625B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/611,301 US7147625B2 (en) 2003-07-01 2003-07-01 Leg bag accessory

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/611,301 US7147625B2 (en) 2003-07-01 2003-07-01 Leg bag accessory

Publications (2)

Publication Number Publication Date
US20050004525A1 US20050004525A1 (en) 2005-01-06
US7147625B2 true US7147625B2 (en) 2006-12-12

Family

ID=33552353

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/611,301 Expired - Fee Related US7147625B2 (en) 2003-07-01 2003-07-01 Leg bag accessory

Country Status (1)

Country Link
US (1) US7147625B2 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120203210A1 (en) * 2011-02-07 2012-08-09 Schanz Richard W Urinary catheter and method
US20130245496A1 (en) * 2012-01-09 2013-09-19 Mark Edward Wells Urinary catheter anti-reflux and pathogen block device
US9122968B2 (en) 2012-04-03 2015-09-01 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US9439334B2 (en) 2012-04-03 2016-09-06 X-Card Holdings, Llc Information carrying card comprising crosslinked polymer composition, and method of making the same
US9861715B2 (en) 2014-09-15 2018-01-09 Observe Medical Aps Body fluid drainage device and method
US10022261B1 (en) 2017-05-31 2018-07-17 Bioderm, Inc. Incontinence device with atmospheric equilibrium valve assembly
US10524982B2 (en) 2015-05-08 2020-01-07 Icu Medical, Inc. Medical connectors configured to receive emitters of therapeutic agents
US10906287B2 (en) 2013-03-15 2021-02-02 X-Card Holdings, Llc Methods of making a core layer for an information carrying card, and resulting products
US11351353B2 (en) 2008-10-27 2022-06-07 Icu Medical, Inc. Packaging container for antimicrobial caps
US11361204B2 (en) 2018-03-07 2022-06-14 X-Card Holdings, Llc Metal card
US11389634B2 (en) 2011-07-12 2022-07-19 Icu Medical, Inc. Device for delivery of antimicrobial agent into trans-dermal catheter
US11400195B2 (en) 2018-11-07 2022-08-02 Icu Medical, Inc. Peritoneal dialysis transfer set with antimicrobial properties
US11413376B2 (en) 2015-03-30 2022-08-16 C. R. Bard, Inc. Application of antimicrobial agents to medical devices
US11433215B2 (en) 2018-11-21 2022-09-06 Icu Medical, Inc. Antimicrobial device comprising a cap with ring and insert
US11497904B2 (en) 2016-10-14 2022-11-15 Icu Medical, Inc. Sanitizing caps for medical connectors
US11517732B2 (en) 2018-11-07 2022-12-06 Icu Medical, Inc. Syringe with antimicrobial properties
US11517733B2 (en) 2017-05-01 2022-12-06 Icu Medical, Inc. Medical fluid connectors and methods for providing additives in medical fluid lines
US11534595B2 (en) 2018-11-07 2022-12-27 Icu Medical, Inc. Device for delivering an antimicrobial composition into an infusion device
US11541220B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Needleless connector with antimicrobial properties
US11541221B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Tubing set with antimicrobial properties
US11684720B2 (en) 2006-06-22 2023-06-27 Excelsior Medical Corporation Antiseptic cap that releases a gas such as nitric oxide
US11730863B2 (en) 2018-07-02 2023-08-22 C. R. Bard, Inc. Antimicrobial catheter assemblies and methods thereof
US11944776B2 (en) 2020-12-07 2024-04-02 Icu Medical, Inc. Peritoneal dialysis caps, systems and methods
US11998715B2 (en) 2014-05-02 2024-06-04 Excelsior Medical Corporation Strip package for antiseptic cap
US12076521B2 (en) 2011-05-23 2024-09-03 Excelsior Medical Corporation Antiseptic cap

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381751B2 (en) * 2003-08-26 2008-06-03 Shantha Sarangapani Antimicrobial composition for medical articles
US20070161949A1 (en) * 2006-01-06 2007-07-12 Knox Susan J Catheter system for minimizing retrograde bacterial transmission from a catheter tubing
US20080027401A1 (en) * 2006-07-28 2008-01-31 Becton, Dickinson And Company Vascular access device filtration
US20110054427A1 (en) * 2009-08-27 2011-03-03 Myles Kobren Male urinary incontinence device and method
US20130195949A1 (en) * 2010-06-29 2013-08-01 Waters Technologies Corporation Antimicrobial Layer For Chromatographic Containers
US20150141965A1 (en) * 2013-11-15 2015-05-21 Celeste V. Bonham Tubing for mitigating against microbial migration and method and system for maintaining closed-system of urinary tubing
US10610677B2 (en) 2014-05-19 2020-04-07 Celeste V. Bonham Urological system that includes connector with integrated non-return check valve for extension tubing and urology collection systems
US20160166802A1 (en) * 2014-12-12 2016-06-16 Bio-Medical Carbon Technology Co., Ltd. Antibacterial catheter
CN105031752B (en) * 2015-07-27 2017-09-12 江苏诚品生物科技有限公司 The drainage system of silver ion antiseptic releasing sleeve
US11052234B2 (en) 2017-02-15 2021-07-06 Celeste V. Bonham Connector with integrated non-return check valve for extension tubing and urology collection systems

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3396727A (en) * 1964-01-06 1968-08-13 Nolte Albert C Jr Drainage tube for body fluids provided with filtering means coated with bacterial preventive material
US4232677A (en) * 1977-06-07 1980-11-11 Saul Leibinsohn Microbe-barrier drainage device
US4417891A (en) * 1981-10-08 1983-11-29 The Kendall Company Collection device with antiseptic liquid for body fluids
US4424058A (en) * 1981-11-23 1984-01-03 Parsons Robert L Drainage control method and apparatus
US4636313A (en) * 1984-02-03 1987-01-13 Vaillancourt Vincent L Flexible filter disposed within flexible conductor
US5207661A (en) * 1991-06-07 1993-05-04 Smiths Industries Public Limited Company Body fluid drainage assembly
US5295979A (en) * 1992-03-27 1994-03-22 P & D Medical Coatings, Inc. Urinary catheter and system
US5300049A (en) * 1987-01-09 1994-04-05 Beth Israel Hospital Assoc. Inc. Closed, fluid-modulating receiving system for the conveyance, modulation, and collection of fluid matter
US5429620A (en) * 1994-08-03 1995-07-04 Uroquest Corporation Calibrated disconnect joint for urethral catheter
US5489281A (en) * 1991-01-18 1996-02-06 Alza Corporation Process for controlling pathogens in container
US5616138A (en) * 1995-08-29 1997-04-01 Tri State Hospital Supply Corporation Urine drainage and collection device
US5762797A (en) * 1995-12-15 1998-06-09 Patrick; Gilbert Antimicrobial filter cartridge
US5766249A (en) * 1990-11-20 1998-06-16 Griffith; Donald P. Tissue bondable cystostomy tube and method of cystostomy tube implantation
US5992413A (en) * 1997-12-24 1999-11-30 Enternet Medical, Inc. Heat and moisture exchanger and generator
US20020030006A1 (en) * 2000-09-08 2002-03-14 Beck Walter O. Tubular filter element
US6540806B2 (en) * 1999-03-24 2003-04-01 Filterwerk Mann & Hummel Gmbh Filter with a cylindrical housing and an annular filter cartridge
US6849214B2 (en) * 1995-12-15 2005-02-01 Microban Products Company Method of making an antimicrobial sintered porous plastic filter

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3396727A (en) * 1964-01-06 1968-08-13 Nolte Albert C Jr Drainage tube for body fluids provided with filtering means coated with bacterial preventive material
US4232677A (en) * 1977-06-07 1980-11-11 Saul Leibinsohn Microbe-barrier drainage device
US4417891A (en) * 1981-10-08 1983-11-29 The Kendall Company Collection device with antiseptic liquid for body fluids
US4424058A (en) * 1981-11-23 1984-01-03 Parsons Robert L Drainage control method and apparatus
US4636313A (en) * 1984-02-03 1987-01-13 Vaillancourt Vincent L Flexible filter disposed within flexible conductor
US5300049A (en) * 1987-01-09 1994-04-05 Beth Israel Hospital Assoc. Inc. Closed, fluid-modulating receiving system for the conveyance, modulation, and collection of fluid matter
US5766249A (en) * 1990-11-20 1998-06-16 Griffith; Donald P. Tissue bondable cystostomy tube and method of cystostomy tube implantation
US5489281A (en) * 1991-01-18 1996-02-06 Alza Corporation Process for controlling pathogens in container
US5207661A (en) * 1991-06-07 1993-05-04 Smiths Industries Public Limited Company Body fluid drainage assembly
US5295979A (en) * 1992-03-27 1994-03-22 P & D Medical Coatings, Inc. Urinary catheter and system
US5429620A (en) * 1994-08-03 1995-07-04 Uroquest Corporation Calibrated disconnect joint for urethral catheter
US5616138A (en) * 1995-08-29 1997-04-01 Tri State Hospital Supply Corporation Urine drainage and collection device
US5762797A (en) * 1995-12-15 1998-06-09 Patrick; Gilbert Antimicrobial filter cartridge
US6849214B2 (en) * 1995-12-15 2005-02-01 Microban Products Company Method of making an antimicrobial sintered porous plastic filter
US5992413A (en) * 1997-12-24 1999-11-30 Enternet Medical, Inc. Heat and moisture exchanger and generator
US6540806B2 (en) * 1999-03-24 2003-04-01 Filterwerk Mann & Hummel Gmbh Filter with a cylindrical housing and an annular filter cartridge
US20020030006A1 (en) * 2000-09-08 2002-03-14 Beck Walter O. Tubular filter element

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12042640B2 (en) 2006-06-22 2024-07-23 Excelsior Medical Corporation Antiseptic cap that releases a gas such as nitric oxide
US11684720B2 (en) 2006-06-22 2023-06-27 Excelsior Medical Corporation Antiseptic cap that releases a gas such as nitric oxide
US11351353B2 (en) 2008-10-27 2022-06-07 Icu Medical, Inc. Packaging container for antimicrobial caps
US20120203210A1 (en) * 2011-02-07 2012-08-09 Schanz Richard W Urinary catheter and method
US12076521B2 (en) 2011-05-23 2024-09-03 Excelsior Medical Corporation Antiseptic cap
US11826539B2 (en) 2011-07-12 2023-11-28 Icu Medical, Inc. Device for delivery of antimicrobial agent into a medical device
US11389634B2 (en) 2011-07-12 2022-07-19 Icu Medical, Inc. Device for delivery of antimicrobial agent into trans-dermal catheter
US20130245496A1 (en) * 2012-01-09 2013-09-19 Mark Edward Wells Urinary catheter anti-reflux and pathogen block device
US10392502B2 (en) 2012-04-03 2019-08-27 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US9688850B2 (en) 2012-04-03 2017-06-27 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US10127489B2 (en) 2012-04-03 2018-11-13 X-Card Holdings, Llc Information carrying card comprising crosslinked polymer composition, and method of making the same
US10255539B2 (en) 2012-04-03 2019-04-09 X-Card Holdings, Llc Information carrying card comprising crosslinked polymer composition, and method of making the same
US11560474B2 (en) 2012-04-03 2023-01-24 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US9122968B2 (en) 2012-04-03 2015-09-01 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US10570281B2 (en) 2012-04-03 2020-02-25 X-Card Holdings, Llc. Information carrying card comprising a cross-linked polymer composition, and method of making the same
US10611907B2 (en) 2012-04-03 2020-04-07 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US10836894B2 (en) 2012-04-03 2020-11-17 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US9439334B2 (en) 2012-04-03 2016-09-06 X-Card Holdings, Llc Information carrying card comprising crosslinked polymer composition, and method of making the same
US11170281B2 (en) 2012-04-03 2021-11-09 Idemia America Corp. Information carrying card comprising crosslinked polymer composition, and method of making the same
US11555108B2 (en) 2012-04-03 2023-01-17 Idemia America Corp. Information carrying card comprising a cross-linked polymer composition, and method of making the same
US11359084B2 (en) 2012-04-03 2022-06-14 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US9183486B2 (en) 2012-04-03 2015-11-10 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US11359085B2 (en) 2012-04-03 2022-06-14 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US11390737B2 (en) 2012-04-03 2022-07-19 X-Card Holdings, Llc Method of making an information carrying card comprising a cross-linked polymer composition
US9594999B2 (en) 2012-04-03 2017-03-14 X-Card Holdings, Llc Information carrying card comprising crosslinked polymer composition, and method of making the same
US9275321B2 (en) 2012-04-03 2016-03-01 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US11884051B2 (en) 2013-03-15 2024-01-30 X-Card Holdings, Llc Methods of making a core layer for an information carrying card, and resulting products
US10906287B2 (en) 2013-03-15 2021-02-02 X-Card Holdings, Llc Methods of making a core layer for an information carrying card, and resulting products
US11998715B2 (en) 2014-05-02 2024-06-04 Excelsior Medical Corporation Strip package for antiseptic cap
US9861715B2 (en) 2014-09-15 2018-01-09 Observe Medical Aps Body fluid drainage device and method
US11413376B2 (en) 2015-03-30 2022-08-16 C. R. Bard, Inc. Application of antimicrobial agents to medical devices
US11759551B2 (en) 2015-03-30 2023-09-19 C. R. Bard, Inc. Application of antimicrobial agents to medical devices
US11559467B2 (en) 2015-05-08 2023-01-24 Icu Medical, Inc. Medical connectors configured to receive emitters of therapeutic agents
US10524982B2 (en) 2015-05-08 2020-01-07 Icu Medical, Inc. Medical connectors configured to receive emitters of therapeutic agents
US11497904B2 (en) 2016-10-14 2022-11-15 Icu Medical, Inc. Sanitizing caps for medical connectors
US11517733B2 (en) 2017-05-01 2022-12-06 Icu Medical, Inc. Medical fluid connectors and methods for providing additives in medical fluid lines
US10022261B1 (en) 2017-05-31 2018-07-17 Bioderm, Inc. Incontinence device with atmospheric equilibrium valve assembly
US11361204B2 (en) 2018-03-07 2022-06-14 X-Card Holdings, Llc Metal card
US11853824B2 (en) 2018-03-07 2023-12-26 X-Card Holdings, Llc Metal card
US11730863B2 (en) 2018-07-02 2023-08-22 C. R. Bard, Inc. Antimicrobial catheter assemblies and methods thereof
US11517732B2 (en) 2018-11-07 2022-12-06 Icu Medical, Inc. Syringe with antimicrobial properties
US11541221B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Tubing set with antimicrobial properties
US11400195B2 (en) 2018-11-07 2022-08-02 Icu Medical, Inc. Peritoneal dialysis transfer set with antimicrobial properties
US11534595B2 (en) 2018-11-07 2022-12-27 Icu Medical, Inc. Device for delivering an antimicrobial composition into an infusion device
US11541220B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Needleless connector with antimicrobial properties
US11433215B2 (en) 2018-11-21 2022-09-06 Icu Medical, Inc. Antimicrobial device comprising a cap with ring and insert
US12109365B2 (en) 2018-11-21 2024-10-08 Icu Medical, Inc Antimicrobial device comprising a cap with ring and insert
US11944776B2 (en) 2020-12-07 2024-04-02 Icu Medical, Inc. Peritoneal dialysis caps, systems and methods

Also Published As

Publication number Publication date
US20050004525A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
US7147625B2 (en) Leg bag accessory
US4479795A (en) Antimicrobial polymer compositions
US4343788A (en) Antimicrobial polymer compositions
US8747882B2 (en) Catheter assembly with bactericidal effect
Tebbs et al. A novel antimicrobial central venous catheter impregnated with benzalkonium chloride
US6183764B1 (en) Microbicide treated polymeric materials
US4392848A (en) Catheterization
EP1363679B1 (en) Combinations of antiseptic and antibiotic agents containing medical devices
US5709672A (en) Silastic and polymer-based catheters with improved antimicrobial/antifungal properties
Bach et al. Prevention of bacterial colonization of intravenous catheters by antiseptic impregnation of polyurethane polymers
EP2754413B1 (en) Medical devices containing nitroprusside and antimicrobial agents
CN106902405A (en) For the device being delivered to antimicrobial in percutaneous catheter
JP5393030B2 (en) Medical device and method for manufacturing medical device
US6361786B1 (en) Microbicide treated polymeric materials
US20050192547A1 (en) Combinations of antiseptic and antibiotic agents containing medical devices
EP0021504B1 (en) Article for use as catheter or the like
Palm et al. Prevention of catheter-related infections by a new, catheter-restricted antibiotic filling technique
Khoury et al. Evaluation of the retrograde contamination guard in a bacteriologically challenged rabbit model
Zhang et al. Antimicrobial modifications on critical care implants
Gilmore et al. Antimicrobial devices
Wijngaerden et al. Intravascular catheter related bloodstream infection: epidemiology, pathogenesis and prevention
KR20220106242A (en) Antibacterial catheter coated with chlorhexidine
MULHALL et al. Development of a catheterised bladder model to evaluate urinary drainage equipment
AU2002337638A1 (en) Combinations of antiseptic and antibiotic agents containing medical devices

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20181212